Eclipsemed collaborates with EndyMed Medical to market the FDA approved radio frequency device

Eclipsemed Ltd, a leading national distributor of advanced medical and aesthetic devices, is pleased to announce that they have collaborated with EndyMed Medical to market the superior EndyMed PRO radio frequency (RF) device to the United States.

The EndyMed PRO has received FDA clearance and is the most advanced RF device on the market today for wrinkle reduction. The EndyMed PRO implements third generation 3DEEP(TM) RF technology, which performs to new levels while enabling the provider to deliver superior treatments safely, comfortably and efficaciously.

Of the numerous RF devices on the market, Eclipse realized that EndyMed had taken radio frequency energy to an optimal clinical level never before seen. The opinion is that the EndyMed PRO will clearly meet the requirements and expectations even of customers that had experienced disappointment with previous RF devices.

"Due to the unique 3DEEP(TM) technology, the radio frequency energy is forced to go where it typically would not travel; but where it needs to travel to have a meaningful clinical effect," says Tom O'Brien, Eclipsemed CEO. "This technology can drive high power controlled and contained energy as deep as 9mm allowing best of breed safety and efficacy levels of treatment."

The EndyMed PRO has proven to be excellent for the reduction of wrinkles, with results that are sustained and have even improved in long term post treatment follow-ups. The EndyMed PRO has the control and safety of a typical bipolar device, yet due to the 3DEEP technology, its efficacy/safety profile is clinically superior to existing bipolar and monopolar RF products on the market today. Additionally, the 3DEEP(TM) technology uniquely allows the delivery of consistent energy into the skin, independently of individual differences in skin impedance. This feature addresses one of the key shortcomings of RF devices today which is inconsistent clinical outcomes resulting from unanticipated changes in tissue impedance.

"We at EndyMed are excited to join forces with Eclipse. Eclipse has an undeniable reputation for successfully bringing leading edge concepts to market. With their proven sales and marketing track record merged with the dynamically advanced EndyMed PRO, 3DEEP technology, I am certain we shall enjoy capturing a significant market share!" says Uzi Blumensohn EndyMed President and CEO.